Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
TAKEDA ANNOUNCES LAUNCH OF EXCHANGE OFFER FOR ANY AND ALL OF ITS $1.250 BILLION 4.000% SENIOR NOTES DUE 2021, $1.500 BILLION 4.400% SENIOR NOTES DUE 2023 AND $1.750 BILLION 5.000% SENIOR NOTES DUE 2028
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
SEE ALL NEWS AND RELEASES >
・For legacy Shire information, click here
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2019 Takeda Pharmaceutical Company Limited. All rights reserved.